ImClone Systems
ImClone Systems Incorporated is a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology. It was founded in 1984 and is headquartered in New York City. On October 6, 2008, it accepted a $6.5 billion acquisition offer from Eli Lilly and Company, and became a fully owned subsidiary of Eli Lilly and Company on November 24, 2008. Prior to the acquisition, it was traded on the NASDAQ stock exchange under the symbol IMCL.
Read more about ImClone Systems: Insider Trading Scandal, Compassionate Use Controversy, Carl Icahn Acquisition, Takeover Offer From Bristol-Myers Squibb, and Subsequent Bidding Showdown, Yeda/Aventis/Imclone Patent Dispute
Famous quotes containing the word systems:
“What is most original in a man’s nature is often that which is most desperate. Thus new systems are forced on the world by men who simply cannot bear the pain of living with what is. Creators care nothing for their systems except that they be unique. If Hitler had been born in Nazi Germany he wouldn’t have been content to enjoy the atmosphere.”
—Leonard Cohen (b. 1934)